Tanay Kaymak
YOU?
Author Swipe
View article: Eosinophilic Esophagitis Pathogenesis: All Clear?
Eosinophilic Esophagitis Pathogenesis: All Clear? Open
Background: Eosinophilic esophagitis (EoE) is a food- and aeroallergen-driven, type 2-mediated chronic inflammation that develops in genetically predisposed individuals with an impaired esophageal epithelial barrier. How pollutants, includ…
View article: Noninvasive Disease Assessment in Eosinophilic Esophagitis With Fractionated Exhaled Nitric Oxide, Blood, and Fecal Biomarkers
Noninvasive Disease Assessment in Eosinophilic Esophagitis With Fractionated Exhaled Nitric Oxide, Blood, and Fecal Biomarkers Open
Background: Eosinophilic Esophagitis (EoE) is a chronic inflammatory condition of the esophagus triggered by food and aeroallergens. There is a need for noninvasive biomarkers that reliably detect EoE in patients with cardinal symptoms and…
View article: IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis
IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis Open
Objective Disruption of the epithelial barrier plays an essential role in developing eosinophilic oesophagitis (EoE), a disease defined by type 2 helper T cell (Th2)-mediated food-associated and aeroallergen-associated chronic inflammation…
View article: Immune system and microbiome in the esophagus: implications for understanding inflammatory diseases
Immune system and microbiome in the esophagus: implications for understanding inflammatory diseases Open
The gastrointestinal tract is the largest compartment of the body's immune system exposed to microorganisms, structural components and metabolites, antigens derived from the diet, and pathogens. Most studies have focused on immune response…
View article: Epithelial GPR35 protects from<i>Citrobacter rodentium</i>infection by preserving goblet cells and mucosal barrier integrity
Epithelial GPR35 protects from<i>Citrobacter rodentium</i>infection by preserving goblet cells and mucosal barrier integrity Open
Summary Goblet cells secrete mucin to create a protective mucus layer against invasive bacterial infection and are therefore essential for maintaining intestinal health. However, the molecular pathways that regulate goblet cell function re…
View article: Lysophosphatidic acid-mediated GPR35 signaling in CX3CR1<sup>+</sup>macrophages regulates the intestinal cytokine milieu
Lysophosphatidic acid-mediated GPR35 signaling in CX3CR1<sup>+</sup>macrophages regulates the intestinal cytokine milieu Open
Summary Single nucleotide polymorphisms in the gene encoding G protein-coupled receptor 35 (GPR35) are associated with increased risk of inflammatory bowel disease. However, the mechanism(s) by which GPR35 modulates the intestinal milieu r…
View article: The Interleukin-20 Cytokines in Intestinal Diseases
The Interleukin-20 Cytokines in Intestinal Diseases Open
Autoimmune/inflammatory intestinal diseases, such as Crohn's disease and ulcerative colitis, infectious gastrointestinal diseases, and gastrointestinal cancers, such as colorectal cancer, are worldwide a significant health problem. Interce…
View article: Supplementary Material for: Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn’s Disease Patients
Supplementary Material for: Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn’s Disease Patients Open
Background: Many patients with moderate to severe Crohn’s disease (CD) are treated with infliximab (IFX). As most of these patients experience a long-lasting therapy, the outcome and withdrawal of IFX treatment are important clinical quest…
View article: Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn’s Disease Patients
Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn’s Disease Patients Open
Background: Many patients with moderate to severe Crohn’s disease (CD) are treated with infliximab (IFX). As most of these patients experience a long-lasting therapy, the outcome and withdrawal of IFX treatment are important clinical quest…